Editorial
Expression of Concern
Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.
N Engl J Med 2005; 353:2813-2814December 29, 2005
- Article
We have recently obtained information regarding inaccuracies in data in the report of the VIGOR (Vioxx Gastrointestinal Outcomes Research) study by Bombardier et al.1 that raise concern about certain conclusions in the article.
The VIGOR study was designed primarily to compare gastrointestinal events in patients with rheumatoid arthritis randomly assigned to treatment with rofecoxib (Vioxx) or naproxen (Naprosyn), but data on cardiovascular events were also monitored. Three myocardial infarctions, all in the rofecoxib group, were not included in the data submitted to the Journal. The editors first became aware of the additional myocardial infarctions in 2001 when updated data were made public by the Food and Drug Administration.
Until the end of November 2005, we believed that these were late events that were not known to the authors in time to be included in the article published in the Journal on November 23, 2000. It now appears, however, from a memorandum dated July 5, 2000, that was obtained by subpoena in the Vioxx litigation and made available to the Journal, that at least two of the authors knew about the three additional myocardial infarctions at least two weeks before the authors submitted the first of two revisions and 4 1/2 months before publication of the article. Given this memorandum, it appears that there was ample time to include the data on these three additional infarctions in the article.
The fact that these three myocardial infarctions were not included made certain calculations and conclusions in the article incorrect. Although only summary percentages, not actual numbers of myocardial infarctions, were included in the Journal article, the following tables display the numerical data without (Table 1Table 1
Data on Myocardial Infarctions Omitting the Three Events.) and with (Table 2Table 2
Data on Myocardial Infarctions Including the Three Events.) the three myocardial infarctions.Lack of inclusion of the three events resulted in an understatement of the difference in risk of myocardial infarction between the rofecoxib and naproxen groups (presented in the article as a reduction in the risk with naproxen but shown here as an increase in the risk with rofecoxib). It also resulted in the misleading conclusion that there was a difference in the risk of myocardial infarction between the aspirin indicated and aspirin not indicated groups.
In addition, the memorandum of July 5, 2000, contained other data on cardiovascular adverse events that we believe would have been relevant to the article. We determined from a computer diskette that some of these data were deleted from the VIGOR manuscript two days before it was initially submitted to the Journal on May 18, 2000.
Taken together, these inaccuracies and deletions call into question the integrity of the data on adverse cardiovascular events in this article. We have asked the authors to submit a correction to the Journal.
This editorial was published on December 8, 2005, at www.nejm.org.
- References
References
1
Bombardier C ,Laine L ,Reicin A , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528
Full Text | Web of Science | Medline
- Citing Articles (29)
Citing Articles
1
Julia Ballard, Chris Graf, Charles Young. (2011) Measuring Clinical Relevance and Impact in Journal Publishing: A Proposed Model and Publisher's Perspective. Clinical Therapeutics 33:12, B11-B15
CrossRef2
Joseph S. Ross, Cary P. Gross, Harlan M. Krumholz. (2011) Promoting Transparency in Pharmaceutical Industry–Sponsored Research. American Journal of Public Healthe1-e9
CrossRef3
C. Gambacorti-Passerini, L. Antolini, F.-X. Mahon, F. Guilhot, M. Deininger, C. Fava, A. Nagler, C. M. Della Casa, E. Morra, E. Abruzzese, A. D'Emilio, F. Stagno, P. le Coutre, R. Hurtado-Monroy, V. Santini, B. Martino, F. Pane, A. Piccin, P. Giraldo, S. Assouline, M. A. Durosinmi, O. Leeksma, E. M. Pogliani, M. Puttini, E. Jang, J. Reiffers, M. G. Valsecchi, D.-W. Kim. (2011) Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. JNCI Journal of the National Cancer Institute 103:7, 553-561
CrossRef4
Zarin, Deborah A., Tse, Tony, Williams, Rebecca J., Califf, Robert M., Ide, Nicholas C., . (2011) The ClinicalTrials.gov Results Database — Update and Key Issues. New England Journal of Medicine 364:9, 852-860
Full Text5
Peter C Gotzsche. (2011) Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 12:1, 249
CrossRef6
Matt Koehler. (2010) Who's calling the shots? The influence of pharmaceutical industry advertising on drug use. Canadian Pharmacists Journal 143:5, 249-251
CrossRef7
Matthias Dahm, Paula González, Nicolás Porteiro. (2010) Implementing registries and results databases of clinical trials: is there a side effect?. Expert Review of Pharmacoeconomics & Outcomes Research 10:3, 247-251
CrossRef8
B D Freeman, C R Kennedy, H L Frankel, B Clarridge, D Bolcic-Jankovic, E Iverson, E Shehane, A Celious, B A Zehnbauer, T G Buchman. (2010) Ethical considerations in the collection of genetic data from critically ill patients: What do published studies reveal about potential directions for empirical ethics research?. The Pharmacogenomics Journal 10:2, 77-85
CrossRef9
JM Ritter. (2009) Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis. British Journal of Clinical Pharmacology 68:5, 647-650
CrossRef10
James M. Ritter, Idris Harding, John B. Warren. (2009) Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends in Pharmacological Sciences 30:10, 503-508
CrossRef11
W. L. Lanier. (2009) Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?. Mayo Clinic Proceedings 84:9, 771-775
CrossRef12
L. J. Hirsch. (2009) Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals. Mayo Clinic Proceedings 84:9, 811-821
CrossRef13
Frank G. Bottone, William T. Barry. (2009) Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999–2002. Current Medical Research and Opinion 25:6, 1535-1550
CrossRef14
Matthew C. Becker, Thomas H. Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F. Lüscher, Jeffrey S. Borer, Alice M. Mascette, M. Elaine Husni, Daniel H. Solomon, David Y. Graham, Neville D. Yeomans, Henry Krum, Frank Ruschitzka, A. Michael Lincoff, Steven E. Nissen. (2009) Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal 157:4, 606-612
CrossRef15
Udaya K Ranawaka, Colvin Goonaratna. (2009) Establishing the Sri Lanka Clinical Trials Registry. Journal of Evidence-Based Medicine 2:1, 29-31
CrossRef16
W. Jaksch, C. Dejaco, M. Schirmer. (2008) 4 years after withdrawal of rofecoxib: where do we stand today?. Rheumatology International 28:12, 1187-1195
CrossRef17
William R. Freudenburg. (2007) Rethinking the Threats to Scientific Balance in Contexts of Litigation and Regulation. Environmental Health Perspectives 116:1, 142-147
CrossRef18
Alexander Lyon. (2007) “Putting Patients First”: Systematically Distorted Communication and Merck's Marketing of Vioxx. Journal of Applied Communication Research 35:4, 376-398
CrossRef19
Aslan T. Turer, Kenneth W. Mahaffey, Kate L. Compton, Robert M. Califf, Kevin A. Schulman. (2007) Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center. American Heart Journal 153:4, 674-680
CrossRef20
Michael Camilleri, Erin C. Dubnansky, Anil K. Rustgi. (2007) Conflicts of Interest and Disclosures in Publications. Clinical Gastroenterology and Hepatology 5:3, 268-273.e1
CrossRef21
Michael Camilleri, Erin C. Dubnansky, Anil K. Rustgi. (2007) Conflicts of Interest and Disclosures in Publications. Gastroenterology 132:3, 841-847
CrossRef22
Deborah F. Spake, Mathew Joseph. (2007) Consumer opinion and effectiveness of direct-to-consumer advertising. Journal of Consumer Marketing 24:5, 283-293
CrossRef23
Japie A Louw. (2006) Peptic ulcer disease. Current Opinion in Gastroenterology 22:6, 607-611
CrossRef24
(2006) News in brief. Nature Reviews Drug Discovery 5:9, 710-711
CrossRef25
Stacy P Ardoin, John S Sundy. (2006) Update on nonsteriodal anti-inflammatory drugs. Current Opinion in Internal Medicine 5:4, 372-377
CrossRef26
James W. Jones, Laurence B. McCullough, Bruce W. Richman. (2006) When the data won’t get you there: The ethics of scientific error, and worse. Journal of Vascular Surgery 43:6, 1308-1310
CrossRef27
Ida Sim, An-Wen Chan, A Metin Gülmezoglu, Tim Evans, Tikki Pang. (2006) Clinical trial registration: transparency is the watchword. The Lancet 367:9523, 1631-1633
CrossRef28
(2006) Response to Expression of Concern Regarding VIGOR Study. New England Journal of Medicine 354:11, 1196-1199
Full Text29
Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2006) Expression of Concern Reaffirmed. New England Journal of Medicine 354:11, 1193-1193
Full Text
- Letters
